Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Open for Active Comparator, Parallel, Multi-center Phase II Study to Explore the Efficacy, Safety and Tolerability of BG2109 Compared With Cetrorelix During COH in Female Subjects Undergoing ART Procedures

NCT05738382 is registered in ClinicalTrials.gov with Bio Genuine (Shanghai) Biotech Co., Ltd. as lead sponsor.

NCT NCT05738382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05738382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Open for Active Comparator, Parallel, Multi-center Phase II Study to Explore the Efficacy, Safety and Tolerability of BG2109 Compared With Cetrorelix During COH in Female Subjects Undergoing ART Procedures
Lead sponsor
Bio Genuine (Shanghai) Biotech Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2023
Completion date
December 31, 2024
Enrollment
240 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

assisted reproductive technology, controlled ovarian hyperstimulation